Use of inhaled corticosteroid; a risk for reduced bone density? A population based study. The bronchial obstruction study in Nord-Trøndelag (BONT) Source: Eur Respir J 2001; 18: Suppl. 33, 442s Year: 2001
Peak bone mineral density (BMD) in children with asthma treated for a mean of 14 years with inhaled budesonide Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Relationship between structural bone changes assessed by ultrasound bone densitometry (UBD) and growth hormone (GH) during chronic treatment with inhaled corticosteroids (ICS) in asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 419s Year: 2003
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R) Source: Eur Respir J 2002; 19: 1058-1063 Year: 2002
The influence of inhalation thechnics at the long application of high dose inhaled corticosteroids on the mineral bone density (MBD) in children Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
The influence of high dose beclomethasone dipropionate (BDP) on bone density in perimenopausal women with bronchial asthma (BA) Source: Eur Respir J 2004; 24: Suppl. 48, 508s Year: 2004
Bone mineral density (BMD) in male patients with chronic obstructive pulmonary disease (COPD) in age 40-70 years Source: Annual Congress 2011 - Morphological and functional imaging in obstructive airway disease Year: 2011
Bone mineral density (BMD) measuring in patients suffering from pulmonary disease under glucocorticoid treatment - fashioned trend or necessity? Source: Eur Respir J 2005; 26: Suppl. 49, 526s Year: 2005
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
The likelihood of low bone mineral density (BMD) in male patients with chronic obstructive pulmonary disease (COPD) in age 40-70 years Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care Year: 2012
Inhaled corticosteroids and bone mineral density in children: A prospective 12-year follow-up study after early-life wheezing Source: Annual Congress 2012 - Treating childhood asthma Year: 2012
Glucocorticosteroid-induced osteoporosis (OP) in postmenopausal women with bronchial asthma (BA) Source: Eur Respir J 2003; 22: Suppl. 45, 419s Year: 2003
E-cadherin (CDH-1 ) polymorphisms associate with airway remodeling, inflammation and FEV1 decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Does chronic assumption of inhaled/per os corticosteroids (Cs) allow osteoporosis/osteopenia (OP) and/or bone fracture (BF) in COLD patients? An epidemiological, observational and transversal survey of an over 50 yrs out-patient cohort Source: Eur Respir J 2006; 28: Suppl. 50, 62s Year: 2006
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Bone mineral density and inhaled budesonide – a systematic review of long-term treatment in children and adults Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013